(Q46970292)

English

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.

scientific article published in February 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. (English)

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

3

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

27 December 2017

author name string

Sanjeev Arora

1

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Christopher O'Brien

2

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Mitchell L Shiffman

4

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Moises Diago

5

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Albert Tran

6

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Paul J Pockros

7

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Robert W Reindollar

8

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Edward Gane

9

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Kavita Patel

10

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Neil Wintfeld

11

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Jesse Green

12

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

publication date

1 February 2006

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

21

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

406-412

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

2

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Chronic hepatitis C with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Impaired health-related quality of life in chronic hepatitis C: the how, but not the why.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Hepatitis C virus infection: quality of life and side effects of treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04059.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2005.04059.X

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

1 reference

Europe PubMed Central

27 December 2017

http://europepmc.org/abstract/MED/16509866

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46970292&oldid=1540620011"